QUICK LINKS
GSK 2606414, serves as a selective inhibitor of protein kinase R-like ER kinase (PERK), displaying an IC50 value of 0.4 nM. In lung carcinoma A549 cells, it effectively inhibits thapsigargin-induced PERK phosphorylation. Moreover, GSK2606414 demonstrates the ability to attenuate the growth of subcutaneous human pancreatic tumor xenografts in mice. Considering that PERK plays a role in the unfolded protein response pathway, which is involved in neurotoxicity and cancer, inhibiting PERK signaling holds potential applications in cancer treatment and cognitive degeneration. Specifically designed as a selective PERK inhibitor, GSK 2606414 effectively hinders PERK activation in cells. This inhibition translates into the suppression of a human tumor xenograft′s growth in mice.
Ordering Information
Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GSK 2606414, 5 mg | sc-490182 | 5 mg | $160.00 | |||
GSK 2606414, 25 mg | sc-490182A | 25 mg | $561.00 |